Related Experiment Video
Updated: Jul 14, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis
G Alanoglu1, S Kilbas, C Arslan
1Department of Internal Medicine, Division of Hematology, School of Medicine, Suleyman Demirel University, 32100 Isparta, Turkey. guchan@med.sdu.edu.tr
Abstract:
A 31-year-old patient with multiple sclerosis (MS), treated with interferon beta-1b (IFNB-1b) for two years, presented with fatigue and dizziness. Coombs' positive autoimmune hemolytic anemia (AIHA) was found. Other potential etiologies of AIHA were ruled out. An association with IFNB-1b was highly suspected. Interferon therapy was discontinued and prednisone therapy instituted. There was resolution of the hemolytic anemia, and prednisone therapy was tapered gradually. To the best of our knowledge, there is no reported case of the development of AIHA associated with IFNB-1b use in MS patients. We conclude that if an unexplained drop in hematocrit occurs with a MS patient receiving IFNB-1b, autoimmune mediated hemolysis should also be considered.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Multiple Sclerosis l: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
